Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Whistleblower: FDA downplayed safety issues at Merck vaccine plant

By Brian Buntz | April 2, 2021

FDA logoA former FDA inspector accused the agency of downplaying safety problems at a Merck plant tapped to manufacture Johnson & Johnson’s COVID-19 vaccine. 

The whistleblower alleged that a 2018 inspection uncovered evidence that employees in the facility in Durham, N.C. engaged in a host of unsanitary practices. A letter to President Biden from the U.S. Office of Special Counsel regarding the Merck plant accuses the company of hiding evidence of employees urinating and defecating in their uniforms rather than taking restroom breaks, which would have required them to leave the manufacturing area and change uniforms. 

A Dec. 2020 Vanity Fair article echoes the assertions, describing the 2018 discovery of a “biohazard nightmare” in the Durham facility. According to a confidential informant who contacted the FDA, “feces had been found smeared on the floor of the plant’s production area.” The confidential informant also reported that employees in the facility moved freely between cleanrooms and other areas of the facility without prescribed gowning changes. 

Although the FDA whistleblower identified evidence to support the confidential informant’s claims, the agency did not follow prescribed procedures for addressing such accusations. FDA also determined that only voluntary action was required at the plant, according to the letter to President Biden from U.S. Special Counsel Henry Kerner. 

“FDA is committed to upholding our mandate to protect and promote public health and ensure that the products we regulate are safe and of high quality for all Americans,” said FDA spokesperson Michael Felberbaum over email. “We take this responsibility seriously and will ensure any concerns raised are reviewed and resolved appropriately.”

Merck stressed in a statement that it prioritizes “the health and safety of patients and our employees and the quality of our medicines and vaccines.” 

“We produce our medicines and vaccines to the highest standards, in full compliance with regulations and good manufacturing practices,” a Merck spokesperson said. “ All of our manufacturing facilities maintain strict, well-documented safety and quality protocols that adhere to, if not exceed, current Good Manufacturing Practices (cGMPs) based on U.S. and international standards.” 

To ensure compliance with CGMP standards, Merck offers comprehensive training to employees and comprehensive internal auditing. “Our vaccines undergo extensive testing prior to release by Merck and also by health authorities and their designated laboratories, in accordance with regulations,” the spokesperson added. 

The letter from Kerner also expresses concern that the FDA has lapsed in its mission to protect and promote the public health. Kerner stated that the whistleblower’s account was sent to former Secretary of Health and Human Services Alex Azar who forwarded it to FDA’s Office of Regulatory Affairs. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. Narendra M Bhojraj says

    April 9, 2021 at 8:02 pm

    This is just unbelievable, I work at a small pharma facility, we have not even started commercial manufacturing, such things do not happen. I think this appears to be a BS story

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

institut pasteur dakar IPD African Union vaccine investment
African Union vaccine initiative receives $45M
Sen-Jam Pharma, KVK-Tech partnering for manufacturing and formulation for anti-inflammatory injectables
This image shows the Moderna logo.
Moderna resizes its manufacturing footprint for a post-pandemic era
This is the logo of Pfizer.
Pfizer to close Durham and Morrisville, North Carolina facilities amid major restructuring effort
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE